Cargando…
Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study
BACKGROUND: Chronotherapy is an innovative approach to improving survival through timed delivery of anti-cancer treatments according to patient daily rhythms. Temozolomide (TMZ) is a standard-of-care chemotherapeutic agent for glioblastoma (GBM). Whether timing of TMZ administration affects GBM pati...
Autores principales: | Damato, Anna R, Luo, Jingqin, Katumba, Ruth G N, Talcott, Grayson R, Rubin, Joshua B, Herzog, Erik D, Campian, Jian L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086242/ https://www.ncbi.nlm.nih.gov/pubmed/33959716 http://dx.doi.org/10.1093/noajnl/vdab041 |
Ejemplares similares
-
Temozolomide Chronotherapy in Glioma: A Systematic Review
por: Jia, Jason L., et al.
Publicado: (2023) -
The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma
por: Xi, Jing, et al.
Publicado: (2021) -
Chronotherapy in Glioblastoma: State of the art and future perspectives
por: Petković, Marina, et al.
Publicado: (2023) -
A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma
por: Butt, Omar H, et al.
Publicado: (2021) -
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
por: Sun, Stella, et al.
Publicado: (2012)